CN103908677A - 肿瘤靶向多肽-阿霉素衍生物及其制备方法和应用 - Google Patents
肿瘤靶向多肽-阿霉素衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN103908677A CN103908677A CN201410137337.7A CN201410137337A CN103908677A CN 103908677 A CN103908677 A CN 103908677A CN 201410137337 A CN201410137337 A CN 201410137337A CN 103908677 A CN103908677 A CN 103908677A
- Authority
- CN
- China
- Prior art keywords
- emch
- doxo
- polypeptide
- amycin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229940009456 adriamycin Drugs 0.000 title abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- OBMJQRLIQQTJLR-USGQOSEYSA-N n-[(e)-[1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)CCCCCN1C(C=CC1=O)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OBMJQRLIQQTJLR-USGQOSEYSA-N 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 20
- 239000000047 product Substances 0.000 claims abstract description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000004237 preparative chromatography Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000003756 stirring Methods 0.000 claims abstract description 5
- 241001597008 Nomeidae Species 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 abstract description 20
- 229930195573 Amycin Natural products 0.000 abstract description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N doxorubicine Natural products O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 14
- 239000000243 solution Substances 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 230000002378 acidificating effect Effects 0.000 abstract description 4
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- -1 adriamycin amycin hydrazone compound Chemical class 0.000 abstract 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 238000000034 method Methods 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 11
- 230000008685 targeting Effects 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 102000002070 Transferrins Human genes 0.000 description 6
- 108010015865 Transferrins Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- XINDHUAGVGCNSF-QSFUFRPTSA-N His-Ala-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XINDHUAGVGCNSF-QSFUFRPTSA-N 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- QAAYIXYLEMRULP-SRVKXCTJSA-N Pro-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 QAAYIXYLEMRULP-SRVKXCTJSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NQVDGKYAUHTCME-QTKMDUPCSA-N Thr-His-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O NQVDGKYAUHTCME-QTKMDUPCSA-N 0.000 description 2
- GEGYPBOPIGNZIF-CWRNSKLLSA-N Trp-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O GEGYPBOPIGNZIF-CWRNSKLLSA-N 0.000 description 2
- AUZADXNWQMBZOO-JYJNAYRXSA-N Tyr-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 AUZADXNWQMBZOO-JYJNAYRXSA-N 0.000 description 2
- AYHNXCJKBLYVOA-KSZLIROESA-N Val-Trp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@@H]3C(=O)O)N AYHNXCJKBLYVOA-KSZLIROESA-N 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010034507 methionyltryptophan Proteins 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108010072106 tumstatin (74-98) Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 238000007445 Chromatographic isolation Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410137337.7A CN103908677B (zh) | 2014-04-04 | 2014-04-04 | 肿瘤靶向多肽‑阿霉素衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410137337.7A CN103908677B (zh) | 2014-04-04 | 2014-04-04 | 肿瘤靶向多肽‑阿霉素衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908677A true CN103908677A (zh) | 2014-07-09 |
CN103908677B CN103908677B (zh) | 2017-02-01 |
Family
ID=51034878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410137337.7A Active CN103908677B (zh) | 2014-04-04 | 2014-04-04 | 肿瘤靶向多肽‑阿霉素衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103908677B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105854025A (zh) * | 2016-04-01 | 2016-08-17 | 南京医科大学 | 多靶点多肽—阿霉素复合物及其制备方法和应用 |
CN107686507A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | Rgds‑阿霉素,其合成,活性和应用 |
CN107686508A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | 阿霉素‑rgds,其合成,活性和应用 |
CN107987132A (zh) * | 2017-10-20 | 2018-05-04 | 南京医科大学 | 一种抗her2多肽-阿霉素复合物及其制备方法和应用 |
CN110386962A (zh) * | 2019-07-04 | 2019-10-29 | 苏州强耀生物科技有限公司 | 一种阿霉素偶联靶向多肽的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010064207A2 (en) * | 2008-12-03 | 2010-06-10 | Koji Kawakami | Selective anticancer chimeric peptide |
CN102048694A (zh) * | 2009-11-06 | 2011-05-11 | 复旦大学 | 一种多肽修饰的肝肿瘤靶向纳米给药系统及其制备方法 |
-
2014
- 2014-04-04 CN CN201410137337.7A patent/CN103908677B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010064207A2 (en) * | 2008-12-03 | 2010-06-10 | Koji Kawakami | Selective anticancer chimeric peptide |
CN102048694A (zh) * | 2009-11-06 | 2011-05-11 | 复旦大学 | 一种多肽修饰的肝肿瘤靶向纳米给药系统及其制备方法 |
Non-Patent Citations (2)
Title |
---|
HEIDI L. PEREZ ET AL.: "Antibody-drug conjugates: current status and future directions", 《DRUG DISCOVERY TODAY》 * |
JAE H. LEE ET AL.: "Receptor mediated uptake of peptides that bind the human transferrin receptor", 《EUR. J. BIOCHEM.》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105854025A (zh) * | 2016-04-01 | 2016-08-17 | 南京医科大学 | 多靶点多肽—阿霉素复合物及其制备方法和应用 |
CN105854025B (zh) * | 2016-04-01 | 2018-11-27 | 南京医科大学 | 多靶点多肽—阿霉素复合物及其制备方法和应用 |
CN107686507A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | Rgds‑阿霉素,其合成,活性和应用 |
CN107686508A (zh) * | 2016-08-05 | 2018-02-13 | 首都医科大学 | 阿霉素‑rgds,其合成,活性和应用 |
CN107686507B (zh) * | 2016-08-05 | 2021-02-12 | 首都医科大学 | Rgds-阿霉素,其合成,活性和应用 |
CN107987132A (zh) * | 2017-10-20 | 2018-05-04 | 南京医科大学 | 一种抗her2多肽-阿霉素复合物及其制备方法和应用 |
CN107987132B (zh) * | 2017-10-20 | 2021-02-26 | 南京医科大学 | 一种抗her2多肽-阿霉素复合物及其制备方法和应用 |
CN110386962A (zh) * | 2019-07-04 | 2019-10-29 | 苏州强耀生物科技有限公司 | 一种阿霉素偶联靶向多肽的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103908677B (zh) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects | |
CN103908677A (zh) | 肿瘤靶向多肽-阿霉素衍生物及其制备方法和应用 | |
CN101254308B (zh) | 甘草次酸-聚乙二醇/壳聚糖肝靶向复合给药系统及制备方法 | |
CN103705940A (zh) | 一种天然活性药物-多糖靶向复合物的制备及其抗肿瘤的应用 | |
CN107158014A (zh) | 无载体共组装肿瘤靶向抗癌纳米药物及其制备方法与应用 | |
CN101942445A (zh) | 核酸适体衍生物及其在制备药物载体中的应用 | |
JináKim et al. | Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity | |
Li et al. | Artificial exosomes mediated spatiotemporal-resolved and targeted delivery of epigenetic inhibitors | |
CN106214640A (zh) | 一种肿瘤靶向递药的脂质体递药系统及制备方法和应用 | |
CN107936058A (zh) | 多西紫杉醇衍生物及其制备方法和应用 | |
Sun et al. | Manipulating endogenous exosome biodistribution for therapy | |
Shao et al. | Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system | |
CN108164584A (zh) | Vap多肽及其在制备靶向诊疗肿瘤药物中的应用 | |
CN107216362A (zh) | 一种阿糖胞苷两亲性小分子前药及其制备方法和应用 | |
CN104208704A (zh) | 一种pH敏感的碳纳米管靶向递药体系的制备方法 | |
CN107573384B (zh) | 一种铱联吡啶配合物及合成方法以及在dna纳米载药系统中的应用 | |
Li et al. | Spatially targeting and regulating tumor-associated macrophages using a raspberry-like micellar system sensitizes pancreatic cancer chemoimmunotherapy | |
Wang et al. | Targeted delivery of hybrid nanovesicles for enhanced brain penetration to achieve synergistic therapy of glioma | |
Xie et al. | Targeted delivery of maytansine to liver cancer cells via galactose-modified supramolecular two-dimensional glycomaterial | |
CN105854025B (zh) | 多靶点多肽—阿霉素复合物及其制备方法和应用 | |
Yang et al. | Discovery of highly potent and selective 7-ethyl-10-hydroxycamptothecin-glucose conjugates as potential anti-colorectal cancer agents | |
Guo et al. | Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy | |
CN103977434B (zh) | 一种对羟基苯甲酸介导的脑靶向聚合物胶束递药系统 | |
Jeong et al. | Preparation of a Camptothecin‐conjugated Molecular Carrier and its Cytotoxic Effect Toward Human Colorectal Carcinoma In Vitro | |
CN102363044B (zh) | 靶向线粒体的三种蒽醌类物质作为鼻咽癌放射增敏剂的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder |
Address after: 210000 Room 601, building B, phase 1, China Dandan Ecological Life Science Park, No. 3-1, new Kumho Road, Jiangbei new district, Nanjing, Jiangsu Patentee after: Nanjing Medical University Address before: 211166 Tianyuan East Road, Jiangning District, Jiangsu, China, No. 818, No. Patentee before: Nanjing Medical University |
|
CP02 | Change in the address of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180419 Address after: 210000 Room 601, building B, phase 1, China Dandan Ecological Life Science Park, No. 3-1, new Kumho Road, Jiangbei new district, Nanjing, Jiangsu Patentee after: Nanjing Ming Jie biopharmaceutical Testing Co., Ltd. Address before: 210000 Room 601, building B, phase 1, China Dandan Ecological Life Science Park, No. 3-1, new Kumho Road, Jiangbei new district, Nanjing, Jiangsu Patentee before: Nanjing Medical University |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tumor targeted polypeptide-adriamycin amycin derivative as well as preparation method and application thereof Effective date of registration: 20190109 Granted publication date: 20170201 Pledgee: Industrial Commercial Bank of China Ltd Nanjing new town science and technology sub branch Pledgor: Nanjing Ming Jie biopharmaceutical Testing Co., Ltd. Registration number: 2019320000022 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191122 Granted publication date: 20170201 Pledgee: Industrial Commercial Bank of China Ltd Nanjing new town science and technology sub branch Pledgor: Nanjing Ming Jie biopharmaceutical Testing Co., Ltd. Registration number: 2019320000022 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tumor targeted polypeptide-adriamycin amycin derivative as well as preparation method and application thereof Effective date of registration: 20200426 Granted publication date: 20170201 Pledgee: Industrial and Commercial Bank of China Limited Nanjing Science and technology sub branch Pledgor: NANJING MILESTONE PHARMA Co.,Ltd. Registration number: Y2020980001794 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |